On May 21, 2026 Novartis reported it will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about sharing our latest advancements in radioligand therapy with new Pluvicto data and early insights from our actinium-based RLT," said Mark Rutstein, MD, Global Head, Oncology Development, Novartis. "With a legacy of bold science, our Kisqali and Scemblix data offer continued evidence of how we meaningfully move cancer treatment forward for patients."

Key ASCO (Free ASCO Whitepaper) data highlights include:

Abstract Title Abstract Number/
Presentation Details
Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Subgroup Analyses by Disease Volume and De Novo/Recurrent mHSPC in the PSMAddition Study of [177Lu]Lu-PSMA-617

225Ac-PSMA-617
AcTION: Phase 1 Study of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With or Without Prior [177Lu]Lu-PSMA (177Lu-PSMA) Radioligand Therapy (RLT) Abstract # 5020
Rapid Oral
May 31, 4:30pm – 6:00pm CDT

Abstract # 5010
Oral
June 1, 3:00pm – 4:30pm CDT

Scemblix (asciminib)

ASC4FIRST wk 144 Analysis: Efficacy and Safety and Tolerability With Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS TKIs) in Newly Diagnosed (ND) chronic myeloid leukemia in Chronic Phase (CML-CP)

Abstract #6583
Poster
June 1, 9:00am – 12:00pm CDT
Kisqali (ribociclib)

Prognostic and Predictive Impact of Baseline Gene Expression (Exp) in the NATALEE Trial of Adjuvant (Adj) Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in HR+/HER2− Early Breast Cancer (EBC)

Abstract #501
Oral
May 30, 1:15pm – 4:15pm CDT
Real-World (RW) Post-Progression Outcomes Following First-Line (1L) Ribociclib (RIB) + Aromatase Inhibitor (AI) Versus AI Alone in African American and Low Socio-Economic Status (SES) Patients (Pts) With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) in the US

Abstract #1073
Poster
June 1, 1:30pm – 4:30pm CDT

Real-World (RW) Post-Progression Outcomes After First-Line (1L) Treatment With Ribociclib + an Aromatase Inhibitor (AI) vs AI Alone in US Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) Abstract # e13044
Online publication

Key EHA (Free EHA Whitepaper) data highlights include: 

Abstract Title Abstract Number/ Presentation Details
Scemblix (asciminib)

ASC4FIRST wk 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Abstract # S160
Oral
June 11, 4:45pm – 6:00pm CEST
Ianalumab (VAY736)
Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results From the VAYHIT2 Phase 3 Trial

Abstract # PF1340
Poster
June 12, 6:45pm – 7:45pm CEST
Pelabresib (DAK539)
Pelabresib Monotherapy in Myelofibrosis After Janus Kinase Inhibitor Failure: Results From Arm 1 of the Open-Label, Phase 2 MANIFEST Study

Abstract # PS1987
Poster
June 13, 6:45pm – 7:45pm CEST
Rapcabtagene autoleucel (YTB323)
Safety, Cellular Kinetics and Early Efficacy of Rapcabtagene Autoleucel (YTB323), a Rapidly Manufactured Autologous CD19 CAR-T Therapy, in Severe, Refractory Autoimmune Diseases

Abstract # PF1241
Poster
June 12, 6:45pm – 7:45pm CEST
Fabhalta (iptacopan)
Iptacopan demonstrates sustained efficacy and safety in paroxysmal nocturnal hemoglobinuria: up to 4 years of follow-up in patients from APPLY, APPOINT and roll-over extension program

Abstract #PS1788
Poster
June 13, 6:45pm – 7:45pm
CEST

Long-term hematologic control and safety in patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: 6-year follow-up from phase 2 studies and roll-over extension program Abstract # PS1797
Poster
June 13, 6:45pm – 7:45pm
CEST

(Press release, Novartis, MAY 21, 2026, View Source [SID1234665899])